M. Galsky

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Matthew D. Galsky, Matt D Galsky, M Galsky, M. D. Galsky, M D Galsky, Matt D. Galsky, Matthew David Galsky, Matthew D Galsky, Matt Galsky, Matthew Galsky, M.d. Galsky
Publication record
759 papers · 28,924 citations · H-index 73

PAPERS

3078P Immune-mediated adverse events (imAEs) associated with sasanlimab in combination with Bacillus Calmette-Guérin (BCG): Phase III study (CREST)
20250 citationsauthor #4
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
202428 citationsauthor #27
PD38-01 NEGATIVE CTDNA STATUS PRIOR TO RADICAL CYSTECTOMY PREDICTS IMPROVED OUTCOMES
20240 citationsauthor #8
PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS OF ANALYSES TO CHARACTERIZE BENEFIT IN RESPONDERS FROM THE PHASE 3 CHECKMATE 901 TRIAL
20240 citationsauthor #20
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
20245 citationsauthor #1
Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma.
20244 citationsauthor #2
Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy
20242 citationsauthor #8
MP61-20 UTILITY OF CIRCULATING TUMOR DNA IN PATIENTS WITH DIFFERENT STAGES OF TESTICULAR CANCER
20240 citationsauthor #3
A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
20230 citationsauthor #3
Extended follow-up results from the CheckMate 274 trial.
202319 citationsauthor #1
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
20237 citationsauthor #20
Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy.
20230 citationsauthor #7
Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
20231 citationsauthor #9
Adaptive Immunity in Genitourinary Cancers.
202314 citationsauthor #5
The effect of statin use on survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted therapies (ART).
20230 citationsauthor #7
Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.
20232 citationsauthor #17
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
20234 citationsauthor #27
A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.
20234 citationsauthor #5
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
20230 citationsauthor #3
C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.
20232 citationsauthor #6
Turning up the heat: CTLA4 blockade in urothelial cancer
20239 citationsauthor #2
Abstract 5648: Single cell spatial phenotyping of bladder tumors with a novel mechanism of NKG2A and HLA-E mediated resistance to BCG immunotherapy
20230 citationsauthor #7
Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
202321 citationsauthor #3
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
202323 citationsauthor #1
Local and systemic therapies for renal cell carcinoma with brain metastases: A single-institution series.
20230 citationsauthor #4
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
20237 citationsauthor #11
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
20232 citationsauthor #29
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
202311 citationsauthor #17
LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
202316 citationsauthor #20
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
20232 citationsauthor #250
Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC).
20230 citationsauthor #14
Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies.
20230 citationsauthor #7
LBA02-08 RESULTS FROM THE EXTENDED FOLLOW-UP IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER IN THE CHeckMATE 274 TRIAL
20230 citationsauthor #2
Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
202316 citationsauthor #7
Abstract LB_A14: Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trials
20230 citationsauthor #19
Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling
20234 citationsauthor #1
CLEP_A_409791 765..773
20230 citationsauthor #1
Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer
202330 citationsauthor #7
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
20232 citationsauthor #7
A phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (SGNTUC-019).
20231 citationsauthor #5
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
202375 citationsauthor #5
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023108 citationsauthor #1
Unraveling myeloid cell-mediated mechanisms of resistance to immune checkpoint blockade in bladder cancer
20230 citationsauthor #8
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
2023310 citationsauthor #24
Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
202321 citationsauthor #2
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
202223 citationsauthor #15
1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy
20220 citationsauthor #7
The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms
20221 citationsauthor #2
Treatment of Metastatic Bladder Cancer
20220 citationsauthor #3
Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms.
20225 citationsauthor #6
663 Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress)
20222 citationsauthor #1
Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology
20224 citationsauthor #7
Androgen Annihilation Versus Advanced Androgen Blockage as First Line Treatment for Metastatic Castration Resistant Prostate Cancer: a systematic review and meta-analysis.
20225 citationsauthor #7
Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy.
20228 citationsauthor #10
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
202222 citationsauthor #2
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
202286 citationsauthor #49
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
202272 citationsauthor #4
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
202217 citationsauthor #2
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
202243 citationsauthor #6
Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring
202211 citationsauthor #8
PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
20224 citationsauthor #1
555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
20220 citationsauthor #1
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
20228 citationsauthor #15
Elevated HLA-E and NKG2A as a Consequence of Chronic Immune Activation Defines Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer
20223 citationsauthor #40
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
202230 citationsauthor #34
NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer
20220 citationsauthor #45
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
20223 citationsauthor #1
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer.
20223 citationsauthor #3
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
202233 citationsauthor #14
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors
202219 citationsauthor #15
Characterization of urine-derived immune cells from bladder cancer patients and comparison to tumor and peripheral blood
20220 citationsauthor #8
Abstract IA24: The evolution of neoadjuvant immunotherapy in bladder cancer
20220 citationsauthor #1
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials
202211 citationsauthor #6
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
20222 citationsauthor #2
Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
202213 citationsauthor #6
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
20225 citationsauthor #1
Usability Inspection of a Mobile Cancer Telerehabilitation System
20226 citationsauthor #4
Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival.
20221 citationsauthor #4
Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations.
202242 citationsauthor #6
Biomarkers for therapy selection in metastatic urothelial cancer
20227 citationsauthor #3
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
20221 citationsauthor #15
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
202242 citationsauthor #18
Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls.
20222 citationsauthor #1
559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients
20220 citationsauthor #32
Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape
20225 citationsauthor #11
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
20228 citationsauthor #7
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
202242 citationsauthor #18
Unfavourable cancer specific survival after neoadjuvant chemotherapy and radical cystectomy in bladder cancer patients with squamous-cell variant: A multi-institutional study
20210 citationsauthor #14
Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial
20212 citationsauthor #3
Opioid use in locally advanced or metastatic urothelial carcinoma patients and matched non-cancer controls.
20211 citationsauthor #7
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
202155 citationsauthor #1
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
202135 citationsauthor #1
708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)
20212 citationsauthor #4
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
202127 citationsauthor #1
PD42-03 HIGH LEVELS OF BASELINE IGG1, IGG3, AND IFN-G MAY BE ASSOCIATED WITH RESISTANCE TO BCG THERAPY FOR TREATMENT OF NMIBC
20210 citationsauthor #19
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
202121 citationsauthor #1
658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)
202117 citationsauthor #1
Immune Checkpoint Blockade for Genitourinary Malignancies and the Abscopal Response
20210 citationsauthor #2
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
202116 citationsauthor #6
699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
202110 citationsauthor #2

TIMELINE

2000 45 citations

2002 0 citations

2003 74 citations

2004 36 citations

2005 277 citations

2006 487 citations

2007 293 citations

2008 164 citations

2009 106 citations

2010 517 citations

2011 1,341 citations

2012 1,623 citations

2013 1,110 citations

2014 1,522 citations

2015 1,187 citations

2016 4,528 citations

2017 4,604 citations

2018 1,134 citations

2019 1,911 citations

2020 5,409 citations

2021 1,187 citations

2022 589 citations

2023 711 citations

2024 39 citations

2025 0 citations

Unknown 0 citations

M. Galsky

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT